Fusion Pharmaceuticals Poised for AstraZeneca Acquisition
Company Announcements

Fusion Pharmaceuticals Poised for AstraZeneca Acquisition

Fusion Pharmaceuticals Inc (FUSN) has released an update.

Fusion Pharmaceuticals Inc. has revealed promising interim data for its prostate cancer treatment, FPI-2265, and is preparing for Phase 2 and 3 trials. Concurrently, the company is set to be acquired by AstraZeneca for up to $2.4 billion, with the transaction likely to conclude in Q2 2024. The deal includes a base purchase price and a contingent value right subject to regulatory milestones.

For further insights into FUSN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskFusion Pharmaceuticals’ Acquisition and Governance Overhaul
TheFlyAstraZeneca completes acquisition of Fusion Pharmaceuticals
TheFlyFusion Pharmaceuticals receives final court order approving AstraZeneca deal
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App